参考文献/References:
[1]卫生部办公厅,国家中医药管理局办公室,总后卫生部. 关于建立抗菌药物临床应用及细菌耐药监测网的通知:国办医发〔2005〕176号[EB/OL].(2005-11-29)[2023-04-17]. http://www.nhc.gov.cn/zwgkzt/pyzgl1/200804/18487.shtml.[2]国家卫生计生委办公厅,国家中医药管理局办公室,解放军总后勤部卫生部药品器材局.关于印发抗菌药物临床应用指导原则(2015年版)的通知:国卫办医发〔2015〕43号[EB/OL].(2015-07-24)[2023-04-17].http://www.nhc.gov.cn/yzygj/s3593/201508/c18e1014de6c45ed9f6f9d592b 43db42.shtml.[3]BRATZLER DW,DELLINGER EP,OLSEN KM,et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery[J].Am J Health Syst Pharm,2013,70(3):195-283.[4]SALM L,MARTI WR,STEKHOVEN DJ,et al.Impact of bodyweight-adjusted antimicrobial prophylaxis on surgical-site infection rates[J].BJS Open, 2020, 5(1):1-6.[5]KOJI Y,KUNIHIRO M,FUMIAKI T,et al.Are bone and serum cefazolin concentrations adequate for antimicrobial prophylaxis?[J].Clin Orthop Relat Res,2011,469(12):3486-3494.[6]CHEN PJ, HUA YM, HAN ST,et al.Topical antibiotic prophylaxis for surgical wound infections in clean and clean-contaminated surgery: a systematic review and meta-analysis[J].BJS Open, 2021,125:1-12.[7]DEPCINSKI SC,NGUYEN KH,ENDER PT.Cefazolin and an aminoglycoside compared with cefazolin alone for the antimicrobial prophylaxis of type III open orthopedic fractures[J].Int J Crit Illn Inj Sci,2019,9(3): 127-131.[8]JONGE SW,GANS SL,JASPER JA,et al.Timing of preoperative antibiotic prophylaxis in 54 552 patients and the risk of surgical site infection a systematic review and meta-analysis[J].Medicine,2017,96(29):1-12.[9]STECCANELLA F,AMORETTI P,BARBIERI MR,et al. Antibiotic prophylaxis for hepato-biliopancreatic surgery—a systematic review[J].Antibiotics,2022,11(2):194.[10]World Health Organization. Global guidelines for the prevention of surgical site infection[Z].2016.[11]BERRIOS TS, UMSCHEID CA, BRATZLER DW, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection[J].JAMA Surg,2017,152(8):784-791.[12]MARIMUTHU C,ABRAHAM V T,RAVICHANDRAN M,et al.Antimicrobial prophylaxis in instrumented spinal fusion surgery: a comparative analysis of 24-hour and 72-hour dosages[J].Asian Spine J,2016,10(6):1018-1022.
相似文献/References:
[1]王凯 顾嘉钦 朱珺 侯旭敏.精细化管理促进辅助药物合理使用[J].中国卫生质量管理,2019,26(03):054.[doi:10.13912/j.cnki.chqm.2019.26.3.16]
[2]赵娴 张青 鹿秀丽 王雨来.基于HIMSS EMRAM 7 标准的合理用药系统建立与应用[J].中国卫生质量管理,2019,26(03):090.[doi:10.13912/j.cnki.chqm.2019.26.3.25]
[3]余雄杰 张静 匡玉霞 陈锦华.应用SAP平台加强抗菌药物临床应用管理[J].中国卫生质量管理,2020,27(02):084.[doi:10.13912/j.cnki.chqm.2020.27.2.26]
[4]王栋罗平刘韶尹桃龚志成.住院患者静脉输液专项管理实践[J].中国卫生质量管理,2022,29(05):034.[doi:10.13912/j.cnki.chqm.2022.29.5.09
]
WANG Dong,LUO Ping,LIU Shao.Special Management Practice of Intravenous Infusion for Inpatients[J].Chinese Health Quality Management,2022,29(04):034.[doi:10.13912/j.cnki.chqm.2022.29.5.09
]
[5]邓明林伟龙时黎明杨谨成安宇杨娟周成诚杨文静.北京市79家医院抗肿瘤药物规范使用现状与影响因素分析[J].中国卫生质量管理,2022,29(11):021.[doi:10.13912/j.cnki.chqm.2022.29.11.06
]
DENG Ming,LIN Weilong,SHI Liming.Current Status and Influencing Factors of Standardized Use of Antitumor Drugs in 79 Hospitals in Beijing[J].Chinese Health Quality Management,2022,29(04):021.[doi:10.13912/j.cnki.chqm.2022.29.11.06
]
[6]李娜马丽平孙晓宇杨威刘倩楠熊康吴奇飞.试点医院抗菌药物管理体系建设与评价[J].中国卫生质量管理,2022,29(12):034.[doi:10.13912/j.cnki.chqm.2022.29.12.08
]
LI Na,MA Liping,SUN Xiaoyu.Construction and Evaluation of Antimicrobial Stewardship in Experimental Hospitals[J].Chinese Health Quality Management,2022,29(04):034.[doi:10.13912/j.cnki.chqm.2022.29.12.08
]
[7]郑婷婷李锦卞婧张威甄健存.以合理用药绩效管理促进医院高质量发展[J].中国卫生质量管理,2022,29(12):047.[doi:10.13912/j.cnki.chqm.2022.29.12.11
]
ZHENG Tingting,LI Jin,BIAN Jing.To Promote the High Quality Development of Hospitals by Performance Management of Rational Drug Use[J].Chinese Health Quality Management,2022,29(04):047.[doi:10.13912/j.cnki.chqm.2022.29.12.11
]
[8]魏伟赵新才张剑萍徐桔密刘杰曹建文郭澄.基于SPO理论的医院抗菌药物管理体系应用探讨[J].中国卫生质量管理,2024,31(03):028.[doi:10.13912/j.cnki.chqm.2024.31.3.08]
WEI Wei,ZHAO Xincai,ZHANG Jianping.Application of Antibiotics Management System in Hospital Based on SPO Theory[J].Chinese Health Quality Management,2024,31(04):028.[doi:10.13912/j.cnki.chqm.2024.31.3.08]
[9]陈熙 府裕琦 吕红梅 赵颖波.我国医疗机构患者自备输注药品管理现状调查分析[J].中国卫生质量管理,2024,31(04):011.[doi:10.13912/j.cnki.chqm.2024.31.4.03]
CHEN Xi,FU Yuqi,LV Hongmei,et al.Investigation and Analysis of Management Status about Patient Self-Provided Infusion Drugs in Medical Institutions in China[J].Chinese Health Quality Management,2024,31(04):011.[doi:10.13912/j.cnki.chqm.2024.31.4.03]